Plain-English translation of NCT06618235 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called , which is an oncolytic virus — a specially designed virus that can attack cancer cells. Researchers will give this medication to patients with advanced ovarian cancer to see if it is safe, well-tolerated, and effective at fighting the disease. The trial will test different doses to find the right amount that works best.
Many patients with advanced ovarian cancer stop responding to standard treatments like platinum-based chemotherapy. This medication offers a new approach — using a virus to directly target and destroy cancer cells — for patients who have limited options left.
You likely qualify if…
You likely don't qualify if…
You will receive as an intravenous infusion during visits to the study center. The trial will test different doses of the medication to find the safest and most effective amount. Throughout the trial, you will have regular check-ups, blood tests, and imaging scans to monitor how your body responds to the treatment and whether your cancer is responding.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Spain
United Kingdom